两种恩替卡韦制剂治疗慢加急性乙型肝炎肝衰竭患者疗效对比研究

doi:10.3969/j.issn.1672-5069.2017.03.011

摘要/Abstract

摘要： 目的对比研究两种恩替卡韦制剂治疗慢加急性乙型肝炎肝衰竭患者的疗效差异。方法 2011年7月~2016年4月我院诊治的慢加急性乙型肝炎肝衰竭患者105例,其中54例接受恩替卡韦分散片（润众）抗病毒治疗的患者为观察组,51例服用恩替卡韦片（博路定）抗病毒治疗的患者为对照组,对比分析两组患者治疗前和治疗12周后血清HBV DNA、肝功能变化的差异,以及12周病死率。结果两组患者治疗后HBV DNA载量均显著下降,其中,观察组第12周HBV DNA载量<500 copies/ml的比例为72.22%（39/54）,对照组为72.55%（37/51）,组间差异无统计学意义（x²=0.03,P=0.86）;与治疗前比,观察组患者治疗12周后血清总胆红素、丙氨酸氨基转移酶、天冬氨酸氨基转移酶水平下降至（66.59±10.78）μmol/L、（68.32±11.57）U/L和（46.77±18.82）U/L,血清白蛋白上升至（37.18±4.29） g/L,PT缩短至（15.34±1.28）s,对照组上述指标变为（65.32±9.18）μmol/L、（67.07±9.62）U/L、（44.17±14.18） U/L、（37.51±4.30） g/L和（15.68±1.27）s,组间差异无统计学意义（P>0.05）;在第12周末,两组患者病死率分别为31.48%（17/54）和31.37%（16/51）,差异无统计学意义（x²=0.04,P=0.84）。治疗期间两组患者均未发生严重不良反应。结论恩替卡韦分散片与恩替卡韦在治疗慢加急性肝衰竭患者的疗效无显著性差异。

关键词: 慢加急性肝衰竭, 乙型肝炎, 恩替卡韦, 疗效

Abstract: Objective To compare the efficacy of domestic and imported entecavir on patients with hepatitis B-induced acute-on-chronic liver failure. Methods 105 patients with hepatitis B-induced acute-on-chronic liver failure between July 2011 and April 2016 in our hospital were included in this clinical trial,and 54 of them were treated with domestic entecavir as observation group,and another 51 patients were treated with imported entecavir as control group. Serum HBV DNA,liver function index,the mortality rate after 12 week treatment were compared between the two groups. Results At the end of 12 weeks,serum HBV DNA levels in the two groups were significantly decreased and the negative rate in the observation group was 72.22% （39/54）,no significant difference as compared to 72.55%（37/51） in the control grou（x²=0.03,P=0.86）;total serum bilirubin,alanine aminotransferase,aspartate aminotransferase levels decreased to（66.59±10.78）μmol/L,（68.32±11.57）U/L,（46.77±18.82）U/L,the serum albumin levels increased to（37.18±4.29）g/L,and PT decreased to（15.34±1.28） s,all of which were not significantly different to those in the control group [（65.32±9.18）μmol/L,（67.07±9.62）U/L,（44.17±14.18）U/L,（37.51±4.30）g/L,（15.68±1.27）,P>0.05];the mortality in the two groups were 31.48%（17/54） and 31.37%（16/51）,and there was no significant difference between the two groups（x²=0.04,P=0.84）. No serious adverse event occurred in the two groups. Conclusions The domestic is equally effective as the imported entecavir in the treatment of patients with hepatitis B-induced acute-on-chronic liver failure.

Key words: Acute-on-chronic liver failure, Hepatitis B, Entecavir, Efficacy

李保欣, 张岁, 段卫, 杨大伟, 郭力红, 王海舫, 贾蓓, 佟立新. 两种恩替卡韦制剂治疗慢加急性乙型肝炎肝衰竭患者疗效对比研究[J]. 实用肝脏病杂志, 2017, 20(3): 298-301.

Li Baoxin, Zhang Sui, Duan Wei, et al.. Comparison of efficacy of domestic and imported entecavir on patients with hepatitis B-induced acute-on-chronic liver failure[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(3): 298-301.

参考文献

[1] 杨玲,曾文铤,谢栩硕,等.HBV C基因区表位变异与慢加急性肝功能衰竭的相关性. 肝脏,2013,18(7):448-451.
[2] 刘菲菲,吴吉圆,张海月,等. 慢加急性乙型肝炎肝衰竭临床特征及血浆置换治疗对其预后的影响.实用肝脏病杂志,2016,19(2):188-191.
[3] Kitrinos KM,Corsa A,Liu Y,et al.No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology,2014,59(2):434-442.
[4] 黄鹏宇. 慢加急性乙型肝炎肝衰竭患者乙型肝炎病毒前C/CP区变异研究进展. 实用肝脏病杂志,2016,19(2):241-244.
[5] 陈丽,罗二平,黄小平等.乙型慢加亚急性肝衰竭患者血清白细胞介素-35的表达及其临床意义.实用医学杂志,2013,29(17):2800-2802.
[6] 黄鹏宇. 慢加急性乙型肝炎肝衰竭患者乙型肝炎病毒前C/CP区变异研究进展. 实用肝脏病杂志,2016,19(2):241-244.
[7] Venkatesh SK,Wang G,Lim SG,et al.Magnetic resonance elastography for the detection and staging of liver fibrosis in chronic hepatitis B. Eur Radiol,2014,24(1):70-78.
[8] 中华医学会感染病学分会肝衰竭与人工肝学组和肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南.实用肝脏病杂志,2013,16(3):210-216.
[9] Marcellin P,Wursthorn K,Wedemeyer H,et al.Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. J Hepatol,2015,62(1):41-47.
[10] 谷茂林,王丽娟. 核苷类似物治疗慢性乙型肝炎患者的HBV序列测定及结果分析. 山东医药,2013,53(33):57-58.
[11] 吴家箴,杨兴祥,江南,等. 应用核苷类似物治疗慢加急性乙型肝炎肝衰竭患者短期疗效观察.实用肝脏病杂志,2015,18(4):413-415.
[12] Seto WK,Hui AJ,Wong VW,et al.Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B:a multicentre prospective study. Gut,2014,64(4):667-672.
[13] 张冬青,陈立,甘巧蓉,等. 慢加急性肝衰竭患者发生肝肾综合征的多因素分析. 中华肝脏病杂志,2013,21(10):743-746.
[14] Rehermann B,Bertoletti A.Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. Hepatology,2015,61(2):712-721.
[15] 戴小灵,钟远辉. 恩替卡韦联合甲基强的松龙冲击治疗乙型肝炎慢加急性肝衰竭的临床效果. 河北医药,2013,35(7):1031-1032.
[16] 梁桂才,黄献球. 拉米夫定与恩替卡韦治疗慢性乙型肝炎慢加急性肝功能衰竭的对比研究. 成都医学院学报,2016,11(1):58-61.
[17] Papatheodoridis GV,Dalekos GN,Yurdaydin C,et al.Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. J Hepatol,2014,62(2):363-370.
[18] 袁明娟,李四海,申红连,等.恩替卡韦分散片联合不同剂量的异甘草酸镁治疗HBeAg阳性慢性乙肝疗效观察.现代中西医结合杂志,2014,23(9):1001-1002.
[19] 闫泰山,孙为鹏,刘杰,等. 恩替卡韦与阿德福韦酯治疗慢性乙型肝炎的成本-效果分析.中国医院药学杂志,2014,34(17):1499-1501.
[20] 王贵霞,曾跃,孟黄花,等. 恩替卡韦分散片治疗慢性乙型肝炎患者48周疗效观察. 临床荟萃,2015,30(8):899-902.
[21] Arends P,Sonneveld JM,Zoutendijk R,et al.Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B:limited role for risk scores in Caucasians. Gut,2015,64(8):1289-1295.
[22] 赖玺杰,杨益大,郑临,等. 恩替卡韦分散片治疗HBeAg阳性慢性乙型肝炎的疗效观察. 中华医院感染学杂志,2016,26(5):988-990.